Advertisement

Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort

Published:October 30, 2018DOI:https://doi.org/10.1016/j.radonc.2018.10.013

      Highlights

      • Observational study of 10-year survival in high-risk Prostate Cancer (PCa) after High-Dose-Rate brachytherapy combined with External Beam Radiation Therapy (HDR-BT/EBRT) compared to EBRT alone.
      • The combined HDR-BT/EBRT treatment was found to give a 3.6-fold decrease in Prostate Cancer Specific Mortality (PCSM) and a 1.6-fold decrease in Overall Mortality (OM).
      • Gleason score and type of treatment strongly influenced PCSM whereas only treatment modality was associated with OM.
      • The observed benefits of dose-escalation warrant future randomized trials.

      Abstract

      Background

      The survival benefit of dose-escalation with High-Dose-Rate brachytherapy (HDR-BT) boost combined with External Beam Radiotherapy (EBRT) for the treatment of high-risk prostate cancer (PCa) remains debatable. We investigated 10-year PCa-specific mortality (PCSM) and overall mortality (OM) in high-risk patients treated with HDR-BT/EBRT (calculated EQD2 = 102 Gy) compared to EBRT alone (70 Gy).

      Methods

      HDR-BT boosts (10 Gy × 2) were given 2 weeks apart followed by 50 Gy conformal EBRT (2 Gy × 25) to the prostate and seminal vesicles. The HDR-BT/EBRT group (N:325) received Androgen Deprivation Therapy for a median duration of 2 years. The historical control group (N:296), received a median dose of 70 Gy (2 Gy × 35) to the prostate and seminal vesicles with lifelong Anti-Androgen Treatment. For each treatment group PCSM and OM were established by competing-risk analyses and Kaplan–Meier analyses respectively. Differences were evaluated by the logrank test. Independent associations were established by Cox regression analyses. Significance level set to p < 0.05.

      Results

      Median follow-up was 104 and 120 months for the HDR-BT/EBRT and the EBRT group respectively. A 3.6-fold decreased risk of PCSM (p < 0.01) and a 1.6-fold decreased risk of OM (p = 0.02) in the HDR-BT/EBRT cohort compared to the EBRT-only group were revealed. Ten-year OM and PCSM rates were 16% and 2.5% in the HDR-BT/EBRT group versus 23% and 8.2% in the EBRT-only group respectively.
      Both treatment modality (HR = 3.59, 95%CI 1.50–8.59) and Gleason score (HR = 2.48, 95%CI 1.18–5.21) were associated with PCSM. Only treatment modality (HR = 1.63, 95%CI = 1.08–2.44) was significantly associated with OM.

      Conclusions

      Men with high-risk PCa have a significantly reduced PCSM and OM rates when treated with dose-escalated radiotherapy achieved by HDR-BT/EBRT compared to EBRT alone (70 Gy). A Gleason score of 8–10 was independently associated with increased risk of PCSM. Randomized studies are warranted.

      Summary

      Observational study of 10-year survival in high-risk Prostate Cancer (PCa) after High-Dose-Rate brachytherapy combined with External Beam Radiation Therapy (HDR-BT/EBRT) compared to EBRT alone. The combined HDR-BT/EBRT treatment was found to give a 3.6-fold decrease in Prostate Cancer Specific Mortality (PCSM) and a 1.6-fold decrease in Overall Mortality (OM). Gleason score and type of treatment strongly influenced PCSM whereas only treatment modality was associated with OM.
      The observed benefits of dose-escalation warrant future randomized trials.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pollack A.
        • Zagars G.K.
        • Smith L.G.
        • Lee J.J.
        • von Eschenbach A.C.
        • Antolak J.A.
        • et al.
        Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.
        J Clin Oncol: Official J Am Soc Clin Oncol. 2000; 18: 3904-3911
        • Horwitz E.M.
        • Bae K.
        • Hanks G.E.
        • Porter A.
        • Grignon D.J.
        • Brereton H.D.
        • et al.
        Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
        J Clin Oncol: Official J Am Soc Clin Oncol. 2008; 26: 2497-2504
        • Fossa S.D.
        • Wiklund F.
        • Klepp O.
        • Angelsen A.
        • Solberg A.
        • Damber J.E.
        • et al.
        Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian prostate cancer group-7.
        Eur Urol. 2016; 70: 684-691
        • Bolla M.
        • Van Tienhoven G.
        • Warde P.
        • Dubois J.B.
        • Mirimanoff R.O.
        • Storme G.
        • et al.
        External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
        Lancet Oncol. 2010; 11: 1066-1073
        • Warde P.
        • Mason M.
        • Ding K.
        • Kirkbride P.
        • Brundage M.
        • Cowan R.
        • et al.
        Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
        Lancet (London, England). 2011; 378: 2104-2111
      1. Guidelines EAU. http://uroweb.org/guideline/prostate-cancer/.

        • Wiegel T.
        • Bartkowiak D.
        • Bottke D.
        • Bronner C.
        • Steiner U.
        • Siegmann A.
        • et al.
        Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.
        Eur Urol. 2014; 66: 243-250
        • Kishan A.U.
        • Cook R.R.
        • Ciezki J.P.
        • Ross A.E.
        • Pomerantz M.M.
        • Nguyen P.L.
        • et al.
        Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9–10 prostate cancer.
        JAMA. 2018; 319: 896-905
        • Galalae R.M.
        • Martinez A.
        • Mate T.
        • Mitchell C.
        • Edmundson G.
        • Nuernberg N.
        • et al.
        Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2004; 58: 1048-1055
        • Hoskin P.J.
        • Rojas A.M.
        • Ostler P.J.
        • Hughes R.
        • Bryant L.
        • Lowe G.J.
        Dosimetric predictors of biochemical control of prostate cancer in patients randomised to external beam radiotherapy with a boost of high dose rate brachytherapy.
        Radiother Oncol: J Eur Soc Therap Radiol Oncol. 2014; 110: 110-113
        • Borghede G.
        • Hedelin H.
        • Holmang S.
        • Johansson K.A.
        • Aldenborg F.
        • Pettersson S.
        • et al.
        Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma.
        Radiother Oncol: J Eur Soc Therap Radiol Oncol. 1997; 44: 237-244
        • Lilleby W.
        • Tafjord G.
        • Raabe N.K.
        Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.
        Int J Radiat Oncol Biol Phys. 2012; 83: 933-939
        • Rodrigues G.
        • Warde P.
        • Pickles T.
        • Crook J.
        • Brundage M.
        • Souhami L.
        • et al.
        Pre-treatment risk stratification of prostate cancer patients: a critical review.
        Can Urol Assoc J. 2012; 6: 121-127
        • Sargos P.
        • Guerif S.
        • Latorzeff I.
        • Hennequin C.
        • Pommier P.
        • Lagrange J.-L.
        • et al.
        Definition of lymph node areas for radiotherapy of prostate cancer: a critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU).
        Cancer Treat Rev. 2015; 41: 814-820
        • Kovacs G.
        • Potter R.
        • Loch T.
        • Hammer J.
        • Kolkman-Deurloo I.K.
        • de la Rosette J.J.
        • et al.
        GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer.
        Radiother Oncol: J Eur Soc Therap Radiol Oncol. 2005; 74: 137-148
        • Lilleby W.
        • Torlakovic G.
        • Torlakovic E.
        • Skovlund E.
        • Fossa S.D.
        Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy.
        Cancer. 2001; 92: 311-319
        • Widmark A.
        • Klepp O.
        • Solberg A.
        • Damber J.E.
        • Angelsen A.
        • Fransson P.
        • et al.
        Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
        Lancet (London, England). 2009; 24373: 301-308
        • Zietman A.L.
        • Bae K.
        • Slater J.D.
        • Shipley W.U.
        • Efstathiou J.A.
        • Coen J.J.
        • et al.
        Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.
        J Clin Oncol: Official J Am Soc Clin Oncol. 2010; 28: 1106-1111
        • Kuban D.A.
        • Tucker S.L.
        • Dong L.
        • Starkschall G.
        • Huang E.H.
        • Cheung M.R.
        • et al.
        Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.
        Int J Radiat Oncol, Biol, Phys. 2008; 70: 67-74
        • Al-Mamgani A.
        • van Putten W.L.
        • van der Wielen G.J.
        • Levendag P.C.
        • Incrocci L.
        Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial).
        Int J Radiat Oncol Biol Phys. 2011; 79: 1004-1012
        • Dearnaley D.P.
        • Sydes M.R.
        • Graham J.D.
        • Aird E.G.
        • Bottomley D.
        • Cowan R.A.
        • et al.
        Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
        Lancet Oncol. 2007; 8: 475-487
        • Dearnaley D.P.
        • Hall E.
        • Lawrence D.
        • Huddart R.A.
        • Eeles R.
        • Nutting C.M.
        • et al.
        Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
        Br J Cancer. 2005; 92: 488-498
        • Morris W.J.
        • Keyes M.
        • Spadinger I.
        • Kwan W.
        • Liu M.
        • McKenzie M.
        • et al.
        Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer.
        Cancer. 2013; 119: 1537-1546
        • Zaorsky N.G.
        • Doyle L.A.
        • Yamoah K.
        • Andrel J.A.
        • Trabulsi E.J.
        • Hurwitz M.D.
        • et al.
        High dose rate brachytherapy boost for prostate cancer: a systematic review.
        Cancer Treat Rev. 2014; 40: 414-425
        • Tarish F.L.
        • Schultz N.
        • Tanoglidi A.
        • Hamberg H.
        • Letocha H.
        • Karaszi K.
        • et al.
        Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair.
        Sci Trans Med. 2015; 7 (312re11)
        • Spratt D.E.
        • Evans M.J.
        • Davis B.J.
        • Doran M.G.
        • Lee M.X.
        • Shah N.
        • et al.
        Androgen receptor upregulation mediates radioresistance after ionizing radiation.
        Cancer Res. 2015; 75: 4688-4696
        • Hoskin P.J.
        • Rojas A.M.
        • Bownes P.J.
        • Lowe G.J.
        • Ostler P.J.
        • Bryant L.
        Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.
        Radiother Oncol: J Eur Soc Therap Radiol Oncol. 2012; 103: 217-222
        • Keyes M.
        • Merrick G.
        • Frank S.J.
        • Grimm P.
        • Zelefsky M.J.
        American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
        Brachytherapy. 2017; 16: 245-265
        • Vigneault E.
        • Mbodji K.
        • Magnan S.
        • Despres P.
        • Lavallee M.C.
        • Aubin S.
        • et al.
        High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes.
        Radiother Oncol: J Eur Soc Therap Radiol Oncol. 2017; 124: 49-55
        • Martinez A.A.
        • Demanes D.J.
        • Galalae R.
        • Vargas C.
        • Bertermann H.
        • Rodriguez R.
        • et al.
        Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
        Int J Radiat Oncol Biol Phys. 2005; 62: 1322-1331
        • Kyrdalen A.E.
        • Dahl A.A.
        • Hernes E.
        • Hem E.
        • Fossa S.D.
        Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs.
        Prostate. 2010; 70: 1480-1489
        • Lilleby W.
        • Stensvold A.
        • Dahl A.A.
        Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life.
        Prostate. 2013; 73: 1038-1047
        • Ryu J.K.
        • Winter K.
        • Michalski J.M.
        • Purdy J.A.
        • Markoe A.M.
        • Earle J.D.
        • et al.
        Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).
        Int J Radiat Oncol, Biol, Phys. 2002; 54: 1036-1046
        • Stark J.R.
        • Perner S.
        • Stampfer M.J.
        • Sinnott J.A.
        • Finn S.
        • Eisenstein A.S.
        • et al.
        Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?.
        J Clin Oncol: Official J Am Soc Clin Oncol. 2009; 27: 3459-3464
        • D'Amico A.V.
        • Keshaviah A.
        • Manola J.
        • Cote K.
        • Loffredo M.
        • Iskrzytzky O.
        • et al.
        Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2002; 53: 581-587
        • Townsend N.C.
        • Ruth K.
        • Al-Saleem T.
        • Horwitz E.M.
        • Sobczak M.
        • Uzzo R.G.
        • et al.
        Gleason scoring at a comprehensive cancer center: what's the difference?.
        J Natl Compr Cancer Network: JNCCN. 2013; 11: 812-819